Zacks Investment Research
24 Jul 2026, 22:51 UTC · 1h ago
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
24 Jul 2026, 22:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
CRISPR Therapeutics (CRSP) is projecting a quarterly revenue increase of 733.26% year-over-year to $7.42 million. — Extreme revenue growth suggests a potential inflection point in commercialization or product adoption.
+0.60CRISPR Therapeutics' full-year revenue is estimated to grow by 722.82% to $28.88 million. — Sustained triple-digit annual growth indicates a strong expansion phase for the company's top line.
+0.50CRISPR Therapeutics' shares decreased 11.95% over the last month, underperforming the Medical sector's 3.64% gain. — Significant relative underperformance suggests bearish sentiment or specific headwinds for the stock.
-0.30Continue reading
6 related stories
Top 3 movers · tap to explore
CRISPR Therapeutics is currently rated as a Zacks Rank #3 (Hold). — A 'Hold' rating implies a neutral outlook with no immediate strong conviction for buying or selling.
Which stocks this story touches
The stock price is down over the last month and lagged the S&P 500 in the most recent session.
Company is seeing a significant increase in page view growth, indicating high investor interest.
Company is seeing a significant increase in page view growth, indicating high investor interest.
Company is seeing a significant increase in page view growth, indicating high investor interest.
Company is seeing a significant increase in page view growth, indicating high investor interest.
Company is seeing a significant increase in page view growth, indicating high investor interest.
Company is seeing a significant increase in page view growth, indicating high investor interest.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
